TF 505Alternative Names: FR-146687; TF-505
Latest Information Update: 31 Mar 2010
At a glance
- Originator Taiho Pharmaceutical
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 30 Jun 2004 Phase-II clinical trials in Benign prostatic hyperplasia in Japan (PO)